Pancreatic Cancer Research

ResearcherUniversity of Rome Tor VergataNo recent work listed

Gianfranco Delle Fave

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112256412. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
62
Papers, trials and grants by year

2013: 3 papers · 2014: none · 2015: 2 papers · 2016: 3 papers · 2017: 4 papers · 2018: 2 papers · 2019: 2 papers

Papers 16

  1. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  2. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  3. Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1177/2050640617752182↗
  4. Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death. Co-author DOI 10.3892/or.2018.6233↗
  5. Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells. Co-author DOI 10.1038/cddis.2017.562↗
  6. Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Co-author DOI 10.1038/s41598-017-13430-z↗
  7. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  8. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients. Co-author DOI 10.3390/ijms18040730↗
  9. Statin Use and Survival in Resectable Pancreatic Cancer: Confounders and Mechanisms. Last author DOI 10.1038/ajg.2015.412↗
  10. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Co-author DOI 10.1038/onc.2015.270↗
  11. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  12. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  13. Early onset pancreatic cancer: risk factors, presentation and outcome. Last author DOI 10.1016/j.pan.2015.01.013↗
  14. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  15. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Co-author DOI 10.1038/onc.2012.306↗
  16. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Co-author DOI 10.1158/1055-9965.epi-12-1182↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gabriele Capurso · 12 shared papers, 2013–2018 · strength 0.73
  2. Lívia Archibugi · 4 shared papers, 2015–2017 · strength 0.28
  3. Claudio Sette · 4 shared papers, 2013–2018 · strength 0.27
  4. Ilaria Passacantilli · 3 shared papers, 2016–2018 · strength 0.23
  5. Roberto Valente · 4 shared papers, 2015–2017 · strength 0.22
  6. Marianna Signoretti · 3 shared papers, 2015–2018 · strength 0.21
  7. Matteo Piciucchi · 3 shared papers, 2015–2017 · strength 0.18
  8. Valentina Panzeri · 2 shared papers, 2017–2018 · strength 0.17
  9. Sara Calabretta · 2 shared papers, 2013–2016 · strength 0.10
  10. Marco J. Bruno · 1 shared paper, 2018 · strength 0.10
  11. Nathalia A. Giese · 3 shared papers, 2013–2017 · strength 0.09
  12. Maria Gazouli · 3 shared papers, 2013–2017 · strength 0.09
  13. Federico Canzian · 3 shared papers, 2013–2017 · strength 0.09
  14. Ľudmila Vodičková · 3 shared papers, 2013–2017 · strength 0.09
  15. Pavel Vodička · 3 shared papers, 2013–2017 · strength 0.09
  16. Renata Talar‐Wojnarowska · 3 shared papers, 2013–2017 · strength 0.09
  17. Daniele Campa · 3 shared papers, 2013–2017 · strength 0.09
  18. Stefano Landi · 3 shared papers, 2013–2017 · strength 0.09
  19. Pavel Souček · 3 shared papers, 2013–2017 · strength 0.09
  20. Raffaele Pezzilli · 3 shared papers, 2013–2017 · strength 0.09
  21. Cosmeri Rizzato · 3 shared papers, 2013–2017 · strength 0.09
  22. Beatrice Mohelníková-Duchoňová · 2 shared papers, 2013–2017 · strength 0.07
  23. Patrick Maisonneuve · 1 shared paper, 2017 · strength 0.07
  24. Michèle Milella · 1 shared paper, 2017 · strength 0.07
  25. Paola Fogar · 2 shared papers, 2013–2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.